Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Schmidinger

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
Anticancer Research|December 30, 2023
Discontinuation of Immune-oncology Combinations due to Immune-related Adverse Events in Patients With Advanced Renal CancersKensuke Bekku, Manuela Schmidinger, Satoshi Katayama, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2003
Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapyRichard Crevenna, Georg Zettinig, Mohammad Keilani, et al.
Critical Reviews in Oncology/Hematology|November 8, 2019
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancersEleonora Rofi, Marzia Del Re, Elena Arrigoni, et al.
European Urology|November 11, 2020
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysisKeiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al.
Critical Reviews in Oncology/Hematology|April 29, 2020
Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancersEleonora Rofi, Marzia Del Re, Elena Arrigoni, et al.
BMC Cancer|September 8, 2010
Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinomaUrsula M Vogl, Marija Bojic, Wolfgang Lamm, et al.
Journal of Neuro-Oncology|June 20, 2021
The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumorAnna Cho, Helena Untersteiner, Fabian Fitschek, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Urologic Oncology|April 21, 2026
Venous thromboembolism in patients with urothelial carcinoma receiving systemic therapyIrene Huebner-Resch, Nicolai A Huebner, Regina Girgis, et al.
European Journal of Neurology|June 2, 2026
Severe Immune-Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single-Center StudyAnna Grisold, Angelika M Starzer, Sara Silvaieh, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
Anticancer Research|December 30, 2023
Discontinuation of Immune-oncology Combinations due to Immune-related Adverse Events in Patients With Advanced Renal CancersKensuke Bekku, Manuela Schmidinger, Satoshi Katayama, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 5, 2003
Quality of life in patients with non-metastatic differentiated thyroid cancer under thyroxine supplementation therapyRichard Crevenna, Georg Zettinig, Mohammad Keilani, et al.
Critical Reviews in Oncology/Hematology|November 8, 2019
Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancersEleonora Rofi, Marzia Del Re, Elena Arrigoni, et al.
European Urology|November 11, 2020
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysisKeiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al.
Critical Reviews in Oncology/Hematology|April 29, 2020
Clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial cancersEleonora Rofi, Marzia Del Re, Elena Arrigoni, et al.
BMC Cancer|September 8, 2010
Extracerebral metastases determine the outcome of patients with brain metastases from renal cell carcinomaUrsula M Vogl, Marija Bojic, Wolfgang Lamm, et al.
Journal of Neuro-Oncology|June 20, 2021
The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumorAnna Cho, Helena Untersteiner, Fabian Fitschek, et al.
ESMO Open|November 16, 2016
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of ViennaBarbara Kiesewetter, Markus Raderer, Günther G Steger, et al.
Urologic Oncology|April 21, 2026
Venous thromboembolism in patients with urothelial carcinoma receiving systemic therapyIrene Huebner-Resch, Nicolai A Huebner, Regina Girgis, et al.
European Journal of Neurology|June 2, 2026
Severe Immune-Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single-Center StudyAnna Grisold, Angelika M Starzer, Sara Silvaieh, et al.
Pageof 12